A new combination therapy designed for some of the most aggressive forms of breast cancer has shown promising results in Phase I clinical in patients living with triple-negative breast cancer (TNBC) which saw 66% of its cohort achieving some form of remission.
The research (NCT04081389), carried out by clinicians at the New York-based Roswell Park Comprehensive Cancer Center saw five of the nine triple-negative breast cancer patients enrolled in the study achieving complete remission with other patients achieving near-complete remission – a total of 66% of patients seeing benefit.
Go deeper with GlobalData
Whilst the research centre saw comparable outcomes for patients who had received a different treatment combination, a major upside of the Roswell Park method was that patients did not experience any immune-related adverse events, which can be serious and sometimes fatal.
Patients received neoadjuvant chemotherapy prior to surgery with the aim of shrinking the tumour. All patients also received a mixture of paclitaxel, known under the brand name Taxol, along with a type of immunotherapy called a chemokine modulatory regimen (CKM). Both work by preventing tumour cells from growing. The CKM regimen included rintatolimod, interferon alfa-2b and celecoxib.
Results from the study’s conclusion, published in the British Medical Journal, found that the combined paclitaxel/CKM regimen was safe, with desirable changes in the tumour microenvironment comparable to the current standard of care in breast cancer treatment.
Shipra Gandhi, lead clinical investigator for the trial, said “We are very excited with these promising results from our study of a new treatment combination for patients with this most highly aggressive form of breast cancer, triple-negative breast cancer. Because this initial study was in a small number of patients, it will be important to validate these findings in a larger study.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataElsewhere in the treatment of breast cancer, Myriad Genetics has announced five research collaborations with health institutions to study the use of its Precise MRD test in molecular residual disease (MRD) testing applications in breast cancer management. Meanwhile, the US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY Rabbit Monoclonal Primary Antibody test designed for biliary tract cancer (BTC).
